Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 12, 2002, Pages 3854-3860

  Stuyver, Lieven J ^a,b   Lostia, Stefania ^a   Adams, Marjorie ^a   Mathew, Judy S ^a   Pai, Balakrishna S ^a   Grier, Jason ^a   Tharnish, Phillip M ^b   Choi, Yongseok ^c   Chong, Youhoon ^c   Choo, Hyunah ^c   Chu, Chung K ^c   Otto, Michael J ^b   Schinazi, Raymond F ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHARMASSET INC   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYCYTIDINE; ACICLOVIR; BETA DEXTRO 2',3' DIDEHYDRO 2',3' DIDEOXY 5 FLUOROCYTIDINE; LAMIVUDINE; NUCLEOSIDE ANALOG; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; MITOCHONDRIAL DNA; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; ENANTIOMER; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS RESISTANCE; ANIMAL; BOVINE DIARRHEA VIRUS; CATTLE; CELL CULTURE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTIVIRAL AGENTS; CATTLE; CELLS, CULTURED; DIARRHEA VIRUSES, BOVINE VIRAL; DNA, MITOCHONDRIAL; DNA, VIRAL; HEPATITIS B VIRUS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STRUCTURE-ACTIVITY RELATIONSHIP; ZALCITABINE;

EID: 0036894245     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.12.3854-3860.2002     Document Type: Article

References (25)

1. Balakrishna Pai, S., S. H. Liu, Y. L. Zhu, C. K. Chu, and Y. C. Cheng. 1996. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyl uracil. Antimicrob. Agents Chemother. 40:380-386.
2. Brinkman, K., J. A. Smeitink, J. A. Romijn, and P. Reiss. 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:1112-1115.
3. Brinkman, K., H. J. ter Hofstede, D. M. Burger, J. A. Smeitink, and P. P. Koopmans. 1998. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 12:1735-1744.
4. Chang, C. N., V. Skalski, J. H. Zhou, and Y.-C. Cheng. 1992. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 267:22414-22420.
5. Colacino, J. M. 1996. Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU). Antivir. Res. 29:125-139.
6. Cui, L., R. F. Schinazi, G. Gosselin, J. L. Imbach, C. K. Chu, R. F. Rando, G. R. Revankar, and J.-P. Sommadossi. 1996. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem. Pharmacol. 52:1577-1584.
7. Cui, L., S. Yoon, R. F. Schinazi, and J.-P. Sommadossi. 1995. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J. Clin. Investig. 95:555-563.
8. Feng, J. Y., A. A. Johnson, K. A. Johnson, and K. S. Anderson. 2001. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J. Biol. Chem. 276:23832-23837.
9. Johnson, A. A., A. S. Ray, J. W. Hanes, Z. Suo, J. M. Colacino, K. S. Anderson, and K. A. Johnson. 2001. Toxicity of nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276:40847-40857.
10. Johnson, M. R., K. Wang, J. B. Smith, M. J. Heslin, and R. B. Diasio. 2000. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 278:175-184.
11. King, R. W., and S. K. Ladner. 2000. Hep AD38 Assay: A High-throughput, Cell-based Screen for the Evaluation of Compounds Against Hepatitis B Virus. Humana Press Inc., Totowa, N.J.
12. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antivir. Res. 19:55-70.
13. Ladner, S. K., M. J. Otto, C. S. Barker, K. Zaifert, G. H. Wang, J. T. Guo, C. Seeger, and R. W. King. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
14. Lai, V. C., W. Zhong, A. Skelton, P. Ingravallo, V. Vassilev, R. O. Donis, Z. Hong, and J. Y. Lau. 2000. Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus. J. Virol. 74:6339-6347.
15. Larder, B. 2001. Mechanisms of HIV-1 drug resistance. AIDS 15:S27-S34.
16. Lewis, W., and M. C. Dalakas. 1995. Mitochondrial toxicity of antiviral drugs. Nat. Med. 1:417-422.
17. Martin, J. L., C. E. Brown, N. Matthews-Davis, and J. E. Reardon. 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:2743-2749.
18. McKenzie, R., M. W. Fried, R. Sallie, H. Conjeevaram, A. M. Di Bisceglie, Y. Park, B. Savarese, D. Kleiner, M. Tsokos, and C. Luciano. 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333:1099-1105.
19. Nam, J. H., J. Bukh, R. H. Purcell, and S. U. Emerson. 2001. High-level expression of hepatitis C virus (HCV) structural proteins by a chimeric HCV/BVDV genome propagated as a BVDV pseudotype. J. Virol. Methods 97:113-123.
20. Pan-Zhou, X. R., L. Cui, X. J. Zhou, J.-P. Sommadossi, and V. M. Darley-Usmar. 2000. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob. Agents Chemother. 44:496-503.
21. Pas, S. D., E. Fries, R. A. De Man, A. D. Osterhaus, and H. G. Niesters. 2000. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J. Clin. Microbiol. 38: 2897-2901.
22. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 Update. Int. Antivir. News 8:65-91.
23. Schinazi, R. F., R. M. J. Lloyd, M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
24. Schinazi, R. F., J. W. Mellors, H. Z. Bazmi, S. Diamond, S. Garber, K. Gallagher, R. Geleziunas, R. Klabe, M. Pierce, M. Rayner, J.-T. Wu, H. Zhang, J. Hammond, L. Bacheler, D. J. Manion, M. J. Otto, L. J. Stuyver, G. Trainor, D. C. Liotta, and S. Erickson-Viitanen. 2002. DPC 817: A cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob. Agents Chemother. 46:1394-1401.
25. Schinazi, R. F., S. Schlueter-Wirtz, and L. J. Stuyver. 2001. Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes. Antivir. Chem. Chemother. 12:61-65.